## Phospho-CD79A (Tyr182) (D1B9) Rabbit mAb (PE Conjugate)



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

## For Research Use Only. Not for Use in Diagnostic Procedures.

<b>Applications:</b> FC-FP	Reactivity: ⊢	<b>Sensitivity:</b> Endogenous	<b>Source/Isotype:</b> Rabbit IgG	UniProt ID: #P11912	Entrez-Gene Id: 973
Product Usage Information		<b>Application</b> Flow Cytometry (Fixed/P	ermeabilized)		<b>Dilution</b> 1:50
Storage		Supplied in PBS (pH 7.2), less than 0.1% sodium azide and 2 mg/ml BSA. Store at 4°C. Do not aliquot the antibodies. Protect from light. Do not freeze.			
Specificity/Sensitivity		Phospho-CD79A (Tyr182) (D1B9) Rabbit mAb (PE Conjugate) recognizes endogenous levels of CD79A protein only when phosphorylated on Tyr188, which corresponds to Tyr182 of mouse CD79A protein.			
Species predicted to react based on 100% sequence homology		Mouse			
Source / Purification		Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr188 of human CD79A protein. This sequence corresponds to Tyr182 of mouse CD79A protein.			
<b>Description</b> This Cell Signaling Technology antibody is conjugated to phycoerythrin (If direct flow cytometry analysis in human cells. The antibody is expected to cross-reactivity as the unconjugated Phospho-CD79A (Tyr182) (D1B9) Rate				d to exhibit the same species	
Background  Antigen receptors found on the surface of B cells contact composed of CD79A and CD79B, also known as Ig α and receptor complex is essential for B cell development at the associated B cell receptor (BCR) initiate intracellula immunoreceptor tyrosine-based activation motif (ITAM appears to be important for its function (6). Antigen bit CD79B heterodimer and subsequent activation of recept that CD79A is a marker for B-lineage lymphoblastic leuthat mutations in the CD79A (MB1) gene are associated receptors in some cases of chronic B cell lymphocytic leads.				g α and Ig β, respecti ent and function (3). ellular signaling follo (ITAM) found in the C en binding precedes receptor associated ic leukemia (8). Addi ciated with abnorma	vely (1,2). Presence of this Together these two proteins and wing antigen binding (4,5). An D79A intracellular region formation of the CD79A and kinases (7). Research has shown tionally, investigators have found
Background References		1. van Noesel, C.J. et al. (1991) <i>J Immunol</i> 146, 3881-8. 2. Minegishi, Y. et al. (1999) <i>J Clin Invest</i> 104, 1115-21. 3. Yu, L.M. and Chang, T.W. (1992) <i>J Immunol</i> 148, 633-7. 4. Storch, B. et al. (2007) <i>Eur J Immunol</i> 37, 252-60. 5. Mason, D.Y. et al. (1995) <i>Blood</i> 86, 1453-9. 6. Luisiri, P. et al. (1996) <i>J Biol Chem</i> 271, 5158-63. 7. Pike, K.A. et al. (2004) <i>J Immunol</i> 172, 2210-8. 8. Astsaturov, I.A. et al. (1996) <i>Leukemia</i> 10, 769-73. 9. Vuillier, F. et al. (2005) <i>Blood</i> 105, 2933-40.			

**Species Reactivity** 

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

**Applications Key** FC-FP: Flow Cytometry (Fixed/Permeabilized)

Cross-Reactivity Key H: Human

**Trademarks and Patents** 

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

## **Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.